Patient characteristics
| . | ZUMA-7 . | Belinda . | Transform . | |||
|---|---|---|---|---|---|---|
| Axi-cel . | SOC . | Tisa-cel . | SOC . | Liso-cel . | SOC . | |
| N | 180 | 179 | 162 | 160 | 92 | 92 |
| Median age, y (range) | 58 (21-80) | 60 (26-81) | 60 (19-79) | 58 (19-77) | 60 (20-74) | 58 (26-75) |
| Age ≥65 y, n (%) | 51 (28) | 58 (32) | 54 (33) | 46 (29) | 36 (39) | 25 (27) |
| Female sex (%) | 70 (39) | 52 (29) | 59 (36) | 62 (39) | 48 (52) | 31 (34) |
| AAIPI* 2-3IPI ≥2 (%) | 82 (46)* | 79 (44)* | 106 (65) | 92 (58) | 36 (39)* | 37 (40)* |
| GCB subgroup (%) | 109 (61) | 99 (55) | 46 (28) | 63 (39) | NR | NR |
| ABC subgroup (%) | 16 (9) | 9 (5) | 52 (32) | 42 (26) | NR | NR |
| HGBCL (%) | 31 (17) | 25 (14) | 32 (20) | 19 (12) | 22 (24) | 21 (23) |
| Refractory to 1L (%) | 133 (74) | 131 (73) | 107 (66) | 107 (67) | 67 (73) | 68 (74) |
| . | ZUMA-7 . | Belinda . | Transform . | |||
|---|---|---|---|---|---|---|
| Axi-cel . | SOC . | Tisa-cel . | SOC . | Liso-cel . | SOC . | |
| N | 180 | 179 | 162 | 160 | 92 | 92 |
| Median age, y (range) | 58 (21-80) | 60 (26-81) | 60 (19-79) | 58 (19-77) | 60 (20-74) | 58 (26-75) |
| Age ≥65 y, n (%) | 51 (28) | 58 (32) | 54 (33) | 46 (29) | 36 (39) | 25 (27) |
| Female sex (%) | 70 (39) | 52 (29) | 59 (36) | 62 (39) | 48 (52) | 31 (34) |
| AAIPI* 2-3IPI ≥2 (%) | 82 (46)* | 79 (44)* | 106 (65) | 92 (58) | 36 (39)* | 37 (40)* |
| GCB subgroup (%) | 109 (61) | 99 (55) | 46 (28) | 63 (39) | NR | NR |
| ABC subgroup (%) | 16 (9) | 9 (5) | 52 (32) | 42 (26) | NR | NR |
| HGBCL (%) | 31 (17) | 25 (14) | 32 (20) | 19 (12) | 22 (24) | 21 (23) |
| Refractory to 1L (%) | 133 (74) | 131 (73) | 107 (66) | 107 (67) | 67 (73) | 68 (74) |
ABC, activated B-cell; GCB, germinal center B cell; HGBCL, high grade B-cell lymphoma; NR, not reported; SOC, standard of care.
Age-adjusted international prognostic index.